What is AMG 176? Understanding this Selective MCL-1 Inhibitor
•
4 min read
In 2019, Amgen voluntarily halted the clinical development of AMG 176 due to a safety signal related to cardiac toxicity. This experimental drug, also known as Tapotoclax, was a highly anticipated agent designed to inhibit the anti-apoptotic protein MCL-1 in various hematologic malignancies.
